These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8079111)

  • 21. Characteristics of Helicobacter pylori alcohol dehydrogenase.
    Salmela KS; Roine RP; Koivisto T; Höök-Nikanne J; Kosunen TU; Salaspuro M
    Gastroenterology; 1993 Aug; 105(2):325-30. PubMed ID: 7687573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
    Bravo LE; Realpe JL; Campo C; Mera R; Correa P
    Am J Gastroenterol; 1999 Sep; 94(9):2380-3. PubMed ID: 10483995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.
    Muñoz DJ; Tasman-Jones C; Pybus J
    Gut; 1992 May; 33(5):592-6. PubMed ID: 1377152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of effects of ethyl alcohol and bismuth subsalicylate on gastric mucosal barrier in man.
    Dy RM; Lof J; DiBaise JK; Quigley EM
    Dig Dis Sci; 1999 Feb; 44(2):286-9. PubMed ID: 10063913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alcohol metabolism in Helicobacter pylori-infected stomach.
    Roine RP; Salmela KS; Salaspuro M
    Ann Med; 1995 Oct; 27(5):583-8. PubMed ID: 8541036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin].
    Ramirez Mayans JA; Zamora Davila E; Cervantes Bustamante R; Mata Rivera N; Oyervides Garcia I; Cuevas S; Zarate Mondragón FE
    Acta Gastroenterol Latinoam; 1996; 26(5):281-3. PubMed ID: 9363265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori.
    Kekilli M; Onal IK; Ocal S; Dogan Z; Tanoglu A
    Saudi J Gastroenterol; 2016; 22(5):366-369. PubMed ID: 27748322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against alcohol-induced gastric mucosal injury by nitecapone.
    Slomiany BL; Piotrowski J; Ismail A; Rajiyah G; Tamura S; Bielanski W; Slomiany A
    Gen Pharmacol; 1991; 22(6):1055-62. PubMed ID: 1810804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of gastric mucosal eicosanoid production in the cytoprotection induced by nitecapone.
    Aho PA; Lindén IB
    Scand J Gastroenterol; 1992; 27(2):134-8. PubMed ID: 1561527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
    Wagner S; Gebel M; Haruma K; Bär W; Lange P; Freise J; Gladziwa U; Schmidt FW
    Gut; 1992 Feb; 33(2):179-83. PubMed ID: 1347278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing the eradication of Helicobacter pylori with triple therapy.
    Graham DY; Lew GM; Malaty HM; Evans DG; Evans DJ; Klein PD; Alpert LC; Genta RM
    Gastroenterology; 1992 Feb; 102(2):493-6. PubMed ID: 1732120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bismuth subcitrate and omeprazole inhibit Helicobacter pyloriF1-ATPase.
    Beil W; Birkholz C; Wagner S; Sewing KF
    Pharmacology; 1995 May; 50(5):333-7. PubMed ID: 7667394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Biochemical and biophysical studies.
    Ottlecz A; Romero JJ; Hazell SL; Graham DY; Lichtenberger LM
    Dig Dis Sci; 1993 Nov; 38(11):2071-80. PubMed ID: 8223083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity.
    Sandha GS; LeBlanc R; Van Zanten SJ; Sitland TD; Agocs L; Burford N; Best L; Mahoney D; Hoffman P; Leddin DJ
    Dig Dis Sci; 1998 Dec; 43(12):2727-32. PubMed ID: 9881506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Helicobacter pylori alcohol dehydrogenase.
    Salaspuro M
    EXS; 1994; 71():185-95. PubMed ID: 8032149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Wagstaff AJ; Benfield P; Monk JP
    Drugs; 1988 Aug; 36(2):132-57. PubMed ID: 3053124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.